Description

Quinupristin is a semisynthetic streptogramin B antibiotic that interrupts the late phase of protein synthesis by binding to the 50S bacterial ribosomal subunit, preventing peptide elongation and causing release of incomplete proteins. When paired with dalfopristin, it exhibits strong synergistic bactericidal activity against Gram-positive organisms, including some drug-resistant strains. Produced under GMP-standard conditions with purity ?98.05%, Quinupristin is suitable for microbiology, antibiotic resistance, and mechanism-of-action research. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Quinupristin disrupts bacterial protein synthesis by binding to the 50S ribosomal subunit and obstructing peptide chain elongation. It works synergistically with dalfopristin, which induces conformational changes on the ribosome to enhance quinupristin’s activity. This combination is highly effective in in vitro models against Gram-positive pathogens, including drug-resistant strains, making it valuable for antibiotic mechanism and resistance studies. For laboratory research use only.

Side Effects (For Reference Only in Models)

While Quinupristin is intended for laboratory use, known effects from clinical use of the combination include inflammation at infusion sites, arthralgia, myalgia, and mild gastrointestinal disturbances. These observations help inform safety assessments within experimental settings. For laboratory research use only.

Disclaimer

 is strictly for laboratory research use only. It is not approved for human or veterinary use. All handling must adhere to institutional safety protocols.